v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenue:        
Total revenue $ 40,078 $ 2,137 $ 58,749 $ 2,137
Operating expenses:        
Cost of sales - product 3,762 318 6,532 318
Cost of sales - intangible amortization 279 128 559 128
Research and development 41,338 24,786 79,555 53,938
Selling, general and administrative 27,409 20,669 49,709 35,692
Total operating expenses 72,788 45,901 136,355 90,076
Loss from operations (32,710) (43,764) (77,606) (87,939)
Other expense (52) (110) (113) (149)
Interest income 1,108 822 2,405 1,782
Interest expense (360) (212) (743) (404)
Loss on debt extinguishment       (1,826)
Change in fair value of warrant liability   20,320 9,323 17,904
Change in fair value of Notes (1,843) (2,990) (3,714) (7,405)
Net loss before taxes (33,857) (25,934) (70,448) (78,037)
Income tax expense (816)   (816)  
Net loss $ (34,673) $ (25,934) $ (71,264) $ (78,037)
Net loss per share-basic (in dollars per share) $ (0.35) $ (0.39) $ (0.72) $ (1.3)
Net loss per share-diluted (in dollars per share) $ (0.35) $ (0.62) $ (0.81) $ (1.41)
Weighted average common shares outstanding used in computing net loss per share - basic (in shares) 100,116 66,143 99,209 60,191
Weighted average common shares outstanding used in computing net loss per share - diluted (in shares) 100,116 74,037 99,634 68,182
Net loss $ (34,673) $ (25,934) $ (71,264) $ (78,037)
Unrealized gain on available-for-sale securities 7      
Change in fair value of Notes attributable to instrument specific credit risk (582) 1,349 2,814 (5,290)
Comprehensive loss (35,248) (24,585) (68,450) (83,327)
Product revenue, net        
Revenue:        
Revenue 25,078 $ 2,137 43,749 $ 2,137
Sale of COPIKTRA license and related assets        
Revenue:        
Revenue $ 15,000   $ 15,000